Table 1.

Demographic and clinicopathologic characteristics of discovery (Phase I) and validation study cohorts

	Phase I		Validation
	Noncancer (%)*	Cancer (%)	Noncancer (%)*	Cancer (%)
	N=46	N=54	N=35	N=35
Median Age (range, y)	56 (20–77)	71 (48–89)	58 (19–85)	67 (20–87)
Male/Female ratio	35:11	47:7	28:13	34:7
Race
White	35 (76)	53 (98)	34 (83)	41 (100)
African American	6 (13)	1 (2)	3 (7)	0 (4)
Other	5 (11)	0 (0)	4 (10)	0 (0)
Positive/suspicious cytology	0 (0)	16 (30)	0 (0)	11 (31)
Clinical stage
Tis	n/a	4 (7)	n/a	0 (0)
Ta	n/a	9 (17)	n/a	14 (34)
T1	n/a	11* (20)	n/a	9 (22)^
T2	n/a	22(41)	n/a	17 (41)^
T3	n/a	2 (4)	n/a	1 (2)
T4		3 (6)		1 (2)
Tx		1 (2)		0
Grade
1/2	n/a	9 (17)	n/a	10 (24)
3	n/a	45 (83)	n/a	31 (76)